[
  {
    "ts": null,
    "headline": "Biogen Inc. stock rises Thursday, still underperforms market",
    "summary": "Biogen Inc. stock rises Thursday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=640770852be4055005b2f6e8b381175ad22d6a6aecc41ce23e85a36aff4be17e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745514480,
      "headline": "Biogen Inc. stock rises Thursday, still underperforms market",
      "id": 134086683,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock rises Thursday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=640770852be4055005b2f6e8b381175ad22d6a6aecc41ce23e85a36aff4be17e"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline",
    "summary": "Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=2d0eabef8e5fcead7d3b1014dd40ec9f019ab431ffe9d3c772d110a8ceabfbd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745503296,
      "headline": "Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline",
      "id": 134068335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=2d0eabef8e5fcead7d3b1014dd40ec9f019ab431ffe9d3c772d110a8ceabfbd8"
    }
  },
  {
    "ts": null,
    "headline": "1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore",
    "summary": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.",
    "url": "https://finnhub.io/api/news?id=65d111117ef81977a5e2f1c6a65fc502b06f9198071ba1cf602067871337f41d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745500173,
      "headline": "1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore",
      "id": 134061597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.",
      "url": "https://finnhub.io/api/news?id=65d111117ef81977a5e2f1c6a65fc502b06f9198071ba1cf602067871337f41d"
    }
  },
  {
    "ts": null,
    "headline": "Can Biogen Keep the Beat Streak Alive This Earnings Season?",
    "summary": "In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.",
    "url": "https://finnhub.io/api/news?id=65fc240d9312ba1e919a2ce748d1b1e99cc78c13c98dce06d3c78cddb24fc76c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745491980,
      "headline": "Can Biogen Keep the Beat Streak Alive This Earnings Season?",
      "id": 134060015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.",
      "url": "https://finnhub.io/api/news?id=65fc240d9312ba1e919a2ce748d1b1e99cc78c13c98dce06d3c78cddb24fc76c"
    }
  },
  {
    "ts": null,
    "headline": "Biogen’s Friedreich’s ataxia treatment authorised in UK",
    "summary": "In a trial, patients showed neurological improvement when treated with the therapy versus a placebo.",
    "url": "https://finnhub.io/api/news?id=a084d6263b0c09485db547c8ac16c272932baf5d5b04cc25de07625a337bf916",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745484862,
      "headline": "Biogen’s Friedreich’s ataxia treatment authorised in UK",
      "id": 134060016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In a trial, patients showed neurological improvement when treated with the therapy versus a placebo.",
      "url": "https://finnhub.io/api/news?id=a084d6263b0c09485db547c8ac16c272932baf5d5b04cc25de07625a337bf916"
    }
  }
]